Novo Nordisk launches long-acting insulin Tresiba

PLAINSBORO, N.J. — Novo Nordisk on Tuesday made available its newest insulin injection Tresiba (insulin degludec). The Food and Drug Administration approved the long-acting, once-daily injection in September 2015. 

 

Tresiba is designed to last at least 42 hours after eight once-a-day injections, and can allow patients to dose themselves at a time that accommodates their schedule. Novo Nordisk is offering a Tresiba Instant Savings Card that can lower co-pays to as little as $15 for 24 months for qualifying patients with commercial insurance. 

 

“When developing new therapies, Novo Nordisk keeps patients' needs top of mind. With its long-acting blood glucose lowering effect, lasting for at least 42 hours, Tresiba is a shining example of that,” Novo Nordisk SVP diabetes marketing Camille Lee said. “We're proud to offer this new treatment for adults living with diabetes and are excited to see the impact it may have on management of their blood sugar.”

 

The company has ensure lowest brand co-pay status on CVS Caremark’s formulary and the drug will be reimbursed at the lowest brand co-pay on SilverScript, Humana Medicare Part D and Humana Medicare Advantage plans. Tresiba will be available in the FlexTouch device in 100 units/mL or 200 units/mL.